ReviewWorld journal of otorhinolaryngology - head and neck surgery2026
Biomarkers Predictive of Immunotherapy Efficacy in Head and Neck Squamous Cell Carcinoma: Current Insights and Future Perspectives.
Review in World journal of otorhinolaryngology - head and neck surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Computational and AI-Enabled Imaging Biomarkers for Predicting and Assessing Immunotherapy Response in Oral Squamous Cell Carcinoma: A Systematic Review with Functional Meta-Synthesis.Medical sciences (Basel, Switzerland) · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With the approval of immunotherapies by regulatory bodies, head and neck squamous cell carcinoma (HNSCC) treatment has been revolutionized, and anti-programmed cell death-1 (anti-PD-1) agents are now the standard for platinum-resistant recurrent/metastatic HNSCC. However, programmed death ligand 1 (PD-L1) expression does not always align with treatment efficacy, and given the risk of immune-related toxicities and high costs, identifying predictive biomarkers is crucial. This review comprehensively examines the current evidence for diverse biomarkers predictive of HNSCC response to anti-PD-1/PD-L1 therapy, including but not limited to PD-L1 expression, tumor mutational burden (TMB), features of the tumor microenvironment (TME), and circulating biomarkers. This integrative approach aims to overcome current limitations, comprehensively evaluate immunotherapy response potential, enhance prognostic assessment, and ultimately guide personalized treatment strategies in clinical practice for HNSCC patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.